We’re building on our fundamental understanding to exploit autocrine signaling pathways and advance our core therapeutic.
Through our combined drug discovery and medical device strategy we continue to evolve into the areas of regenerative medicine with highest unmet needs and opportunities.
Autocrine driving-force at work
The lead TCPTP agonist, TP7193, was selected by rationale high-throughput screening. TP7193 activation of TCPTP leads to the down-regulation of stress signaling, while up-regulates the cell-to-cell bond proteins fostering the phenotype stabilization. Compelling preclinical evidences support the TP7193 vascular protection and neurotrophic activity (close to NGF). Further features include autophagic renewal of aged cells and the inhibitive/passive dilution of TG2 catalyzed fibrotic patterns.